Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Philippe Durand

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Expert Opinion on Drug Safety|April 4, 2014
Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patientsOlivier Huillard, Emilie Boissier, Benoit Blanchet, et al.
Lung Cancer (Amsterdam, Netherlands)|February 28, 2012
Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancerOlivier Mir, Pascaline Boudou-Rouquette, Julie Giroux, et al.
Expert Opinion on Drug Metabolism & Toxicology|March 27, 2015
Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenibCamille Tlemsani, Olivier Huillard, Jennifer Arrondeau, et al.
Expert Opinion on Investigational Drugs|January 21, 2015
Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeuticsJennifer Arrondeau, Olivier Huillard, Camille Tlemsani, et al.
Clinical Nutrition (Edinburgh, Scotland)|February 2, 2017
Resting energy expenditure in the risk assessment of anticancer treatmentsAnne Jouinot, Clara Vazeille, Jean Philippe Durand, et al.
Clinical Nutrition (Edinburgh, Scotland)|August 15, 2025
Early nutritional and inflammation assessment predicts prognosis in patients with cancer across tumor origin and metastatic statusJuliette Renard, Jean-Philippe Durand, Sixtine De Percin, et al.
Plos One|August 23, 2012
Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary studyPascaline Boudou-Rouquette, Céline Narjoz, Jean Louis Golmard, et al.
Clinical Nutrition ESPEN|September 7, 2024
Relationship between energetic gap and sensitivity to anti-programmed cell death 1 immune checkpoint inhibitors in non-small cell lung cancer patients: The ELY-2 studyManuela Tiako Meyo, Pascaline Boudou-Rouquette, Jennifer Arrondeau, et al.
Pharmaceutical Research|June 22, 2011
Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patientsMichel Tod, Olivier Mir, Natacha Bancelin, et al.
Clinical Nutrition (Edinburgh, Scotland)|April 11, 2022
Energy expenditure profiles and the risk of early limiting toxicity in older patients with cancer: The ELCAPA-25 prospective cohort surveyPascaline Boudou-Rouquette, Alexandre de Moura, Claudia Martinez-Tapia, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Expert Opinion on Drug Safety|April 4, 2014
Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patientsOlivier Huillard, Emilie Boissier, Benoit Blanchet, et al.
Lung Cancer (Amsterdam, Netherlands)|February 28, 2012
Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancerOlivier Mir, Pascaline Boudou-Rouquette, Julie Giroux, et al.
Expert Opinion on Drug Metabolism & Toxicology|March 27, 2015
Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenibCamille Tlemsani, Olivier Huillard, Jennifer Arrondeau, et al.
Expert Opinion on Investigational Drugs|January 21, 2015
Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeuticsJennifer Arrondeau, Olivier Huillard, Camille Tlemsani, et al.
Clinical Nutrition (Edinburgh, Scotland)|February 2, 2017
Resting energy expenditure in the risk assessment of anticancer treatmentsAnne Jouinot, Clara Vazeille, Jean Philippe Durand, et al.
Clinical Nutrition (Edinburgh, Scotland)|August 15, 2025
Early nutritional and inflammation assessment predicts prognosis in patients with cancer across tumor origin and metastatic statusJuliette Renard, Jean-Philippe Durand, Sixtine De Percin, et al.
Plos One|August 23, 2012
Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary studyPascaline Boudou-Rouquette, Céline Narjoz, Jean Louis Golmard, et al.
Clinical Nutrition ESPEN|September 7, 2024
Relationship between energetic gap and sensitivity to anti-programmed cell death 1 immune checkpoint inhibitors in non-small cell lung cancer patients: The ELY-2 studyManuela Tiako Meyo, Pascaline Boudou-Rouquette, Jennifer Arrondeau, et al.
Pharmaceutical Research|June 22, 2011
Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patientsMichel Tod, Olivier Mir, Natacha Bancelin, et al.
Clinical Nutrition (Edinburgh, Scotland)|April 11, 2022
Energy expenditure profiles and the risk of early limiting toxicity in older patients with cancer: The ELCAPA-25 prospective cohort surveyPascaline Boudou-Rouquette, Alexandre de Moura, Claudia Martinez-Tapia, et al.
Pageof 4